Ocular Therapeutix Stock News

Ocular Therapeutix, Inc. (NASDAQ:OCUL) was the target of a significant decline in short interest during the month of October. As of October 29th, there was short interest totalling 4,030,000 shares, a decline of 14.6% from the October 14th total of 4,720,000 shares. Currently, 5.3% of the companys stock are sold short. Based on an average []

Ocular Therapeutix Inc. (NASDAQ:OCUL) price on Friday, November 19, fall -0.30% below its previous days close as a downside momentum from buyers pushed the stocks value to $6.69. A look at the stocks price movement, the close in the last trading session was $6.71, moving within a range at $6.58 and $6.88. The beta value Ocular Therapeutix Inc. (OCUL) Is Worth Thinking About For The Coming Weeks Read More »

With valuations under $2 billion at the moment, these stocks have a lot of room to climb.

With valuations under $2 billion at the moment, these stocks have a lot of room to climb.

Corvus Pharmaceuticals (NASDAQ:CRVS) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Risk & Volatility Corvus Pharmaceuticals has a beta of 0.93, suggesting that its stock price […]

Ocular Therapeutix (NASDAQ:OCUL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Profitability This table compares Ocular Therapeutix and Corvus Pharmaceuticals’ net margins, return on equity and […]

Ocular Therapeutix, Inc. (NASDAQ:OCUL)s share price shot up 6.9% during trading on Monday . The company traded as high as $7.49 and last traded at $7.45. 2,483 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 1,012,380 shares. The stock had previously closed at $6.97. A number of []

Ocular Therapeutix Inc. (NASDAQ:OCUL) price closed lower on Friday, November 12, dropping -7.19% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Ocular Therapeutix (NASDAQ:OCUL) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet []

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2021 Results - Earnings Call Transcript

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 11.54% and 0.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t

Biotech stocks that fall hard on bad news can rebound in a flash.

The company's experimental dry-eye treatment produced some disappointing clinical trial results.